The Department of Clinical Pathology has a number of exciting opportunities for masters and honours students in 2023.
Our dynamic Honours and Masters programs offer pathology-focused coursework and a range of ground-breaking research projects focused on improving outcomes for cancer patients.
Interactive tutorials are dedicated to developing critical analysis skills, with additional seminars introducing students to technical and conceptual advances in clinical pathology and to the integration of lab- and computer-based Clinical Pathology research.
Scholarships and awards
Several $1,500 bursaries will be awarded to students with an outstanding academic record who join one of our 2023 projects.
Students undertaking the following projects will be eligible to apply for scholarships and awards with a combined worth of over $60,000 annually from both the Department of Clinical Pathology and the University of Melbourne Centre for Cancer Research, including the $2,000 J.E. Taylor Honours Award for the top student undertaking a cancer-related Honours project in the Department of Clinical Pathology.
Our program also provides an opportunity for students to engage with consumers and clinicians and to understand how community and consumer engagement is an essential component of modern Pathology research.
See details of our current project opportunities below, and get in touch for more information.
Our researchers are leaders in diagnosis, treatment and prevention of cancer to improve the lives of patients. Based in the Victorian Comprehensive Cancer Centre (VCCC), we collaborate broadly with other Departments, Centres, Schools and Faculties of the University of Melbourne, health services, and medical research institutes, to collaborate on and improve cancer research.
2023 Masters and Honours Projects
Molecular and pharmacological validation of rationally-designed combination treatments in pancreatic cancer
This project will contribute to the characterisation of new drug targets that most efficiently synergise with chemotherapy to eradicate pancreatic cancer cells, allowing the development of robust drug candidates to improve clinical outcome for patients with this disease.
Detecting DNA mismatch repair gene mosaicism
The project will involve developing sensitive droplet digital PCR assays to screen for MMR gene variants in multiple tissue sources from an existing patient group in the ANGELS study.